Post by BiotechTV

Name: 𝐁𝐈𝐎 𝟐𝟎𝟐𝟔: HAYA Therapeutics is focused on how the non-coding "regulatory" portion of the geno
Uploaded: 2026-06-22T20:02:05.703Z
Channel: BiotechTV
Description: 𝐁𝐈𝐎 𝟐𝟎𝟐𝟔: HAYA Therapeutics is focused on how the non-coding "regulatory" portion of the genome causes disease. Its first program targeting cardiac fibrosis is now in the clinic in healthy volu

39,119 followers

𝐁𝐈𝐎 𝟐𝟎𝟐𝟔: HAYA Therapeutics is focused on how the non-coding "regulatory" portion of the genome causes disease. Its first program targeting cardiac fibrosis is now in the clinic in healthy volunteers. #BIO2026 Full video: https://lnkd.in/dw928QvG HAYA Co-Founder & CEO Samir Ounzain discusses the WISPER target that came out of the company's work of cataloging long non-coding RNAs, and the role that downregulating it might play in stopping the progression of nonobstructive hypertrophic cardiomyopathy. Plus, other programs, and where an understanding of the regulatory portion of the genome could ultimately take us. BiotechTV's coverage of BIO 2026 is brought to you by Evaluate Ltd. BiotechTV is brought to you by: Mispro | HSBC Innovation Banking | 10x Genomics | Allucent | NYSE | Klein Hersh | Genezen | Orchestra | Evaluate Ltd

Video Content